Silencing/Overexpressing selected genes as a model of sporadic parkinson's disease

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 108-111

  Fishman Jacob, Tali ^a   Youdim, Moussa B H ^a   Mandel, Silvia A ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cell culture model; Cell cycle; Cullin; Dopaminergic markers; F box complex; Short hairpin RNA; SKP1; Sporadic Parkinson's disease

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE A1; NEUROTOXIN; NEUROTROPHIN; PROTEIN SKP1A; SHORT HAIRPIN RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL CYCLE; CONFERENCE PAPER; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC MODEL; KNOCKOUT GENE; LENTIVIRINAE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; PARKINSON DISEASE; RNA INTERFERENCE; SILENCER ELEMENTS, TRANSCRIPTIONAL; UBIQUITIN-PROTEIN LIGASES;

EID: 76749132743     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000285517     Document Type: Conference Paper

References (17)

1. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
2. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al: Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006; 5: 845-854.
3. Mandel S, Amit T, Kalfon L, Youdim MB: Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery. Exp Opin Drug Disc 2007; 2: 1225-1240.
4. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al: Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress-regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004; 111: 1543-1573.
5. Mandel SA, Fishman T, Youdim MB: Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. Parkinsonism Relat Disord 2007; 13(suppl 3):242-247.
6. Feldman RM, Correll CC, Kaplan KB, Deshaies RJ: A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 1997; 91: 221-230.
7. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al: Structure of the Cul1-Rbx1-Skp1-f Boxskp2 Scf ubiquitin ligase complex. Nature 2002; 416: 703-709.
8. Ciechanover A, Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40: 427-446.
9. Dawson TM, Dawson VL: Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-822.
10. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608. (Pubitemid 28207717)
11. Galter D, Buervenich S, Carmine A, Anvret M, Olson L: Aldh1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis 2003; 14: 637-647.
12. Agid Y, Javoy F, Youdim MB: Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol 1973; 48: 175-178.
13. Duncan RJ, Sourkes TL, Boucher R, Poirier LJ, Roberge A: Aldehyde dehydrogenase and monoamine oxidase in the striatum of cats with nigrostriatal lesions. J Neurochem 1972; 19: 2007-2010.
14. Hjelle JJ, Petersen DR: Hepatic aldehyde dehydrogenases and lipid peroxidation. Pharmacol Biochem Behav 1983; 18(suppl 1):155-160.
15. Mardh G, Vallee BL: Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine. Biochemistry 1986; 25: 7279-7282.
16. Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA: Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics 2009; 6: 128-140.
17. Fishman-Jacob T, Reznichenko L, Youdim MBH, Mandel SA: A sporadic Parkinson disease model via silencing the ubiquitin-proteasome/ E3-ligase component, SKP1A. J Biol Chem 2009;284:32835-32845.